PERL - A multicenter clinical trial of allopurionol to prevent GFR loss in type 1 diabetes

The aim is to determine whether lowering serum uric acid by means of allopurinol early in the course of kidney disease may be effective in preventing or slowing the decline of renal function in T1D patients.

Design and method

Multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial. There are 17 visits of ½-4 hours duration over a period of 3 years and 3 months.

Target group

  • Have type 1 diabetes
  • Between 18 and 70 years old
  • Have microalbuminuria or moderate macroalbuminuria
  • Have an estimated kidney function between 40 – 99.9 ml/min/1.73 m2
  • Have a blodpressure under 160/100 mmHg
  • Have not previously had a arthritis diagnosis

Expected ending and outcome

The Project started in December 2012 and are expected to end March 2019. The recruitment process has ended and we are not looking for more participants.


Alessandro Doria, MD PhD MPH 
Joslin Diabetes Center and Harvard Medical School
Boston, USA.